Cencora (0HF3.L) Bundle
Who is buying AmerisourceBergen Corporation (0HF3.L) and why does it matter to your portfolio? With institutional ownership at a striking 90.6%, major financial players are staking claims: The Vanguard Group holds 12,940,000 shares (≈9.8%) and boosted its stake by 1.2%, while BlackRock controls 10,580,000 shares (≈8.0%) despite a 0.5% trim; State Street, Wellington, Fidelity and Geode all show shifts-State Street at 7,210,000 shares (≈5.5%, +0.3%), Wellington with 5,020,000 (≈3.8%, +0.1% and a new 300,000-share position), FMR at 4,800,000 (≈3.7%, +0.2%) and Geode ramping up holdings by 11%-signals that institutional conviction and tactical repositioning are driving sentiment. Market indicators compound the story: the stock hit an all-time high of $253.67 on January 27, 2025, the company exhibits a low beta of 0.56 suggesting lower volatility, analysts have raised FY2025 adjusted EPS estimates, and strategic moves-from the Aug 2023 rebranding to Cencora to the Retina Consultants of America acquisition (estimated to add ≈$0.35 to first-year earnings) and expansion into specialty drugs with a new California distribution center-paint a picture of growth that institutional owners are clearly betting on; dive into the full breakdown to see which investors are leading the charge and what their moves imply for future performance
AmerisourceBergen Corporation (0HF3.L) - Who Invests in AmerisourceBergen Corporation (0HF3.L) and Why?
AmerisourceBergen attracts a mix of large passive index managers and active institutional investors drawn to its scale in pharmaceutical distribution, margin resilience, recurring revenue streams from healthcare supply chains, and strategic investments in specialty logistics and services.- The Vanguard Group - ~10%: index and active funds favoring healthcare sector exposure and long-term core holding.
- BlackRock, Inc. - ~9.5%: broad ETF/index allocation plus active faith in cash flow generation and dividend profile.
- Wellington Management Co. LLP - ~7.5%: active manager positioning for growth in specialty distribution and margin pickup.
- State Street Corporation - ~5.7%: institutional index/ETF exposure representing stability-focused investors.
- FMR LLC (Fidelity) - ~4.3%: selective active conviction in operational improvements and earnings durability.
- Geode Capital Management - ~3.5%: systematic/global equity strategies seeking efficient healthcare exposure.
| Holder | Estimated Ownership | Investment Motive |
|---|---|---|
| The Vanguard Group | ~10% | Core index and active fund allocations; long-term growth and stable dividends |
| BlackRock, Inc. | ~9.5% | ETF/index exposures plus conviction in cash flow and scale |
| Wellington Management Co. LLP | ~7.5% | Active position for specialty distribution growth opportunities |
| State Street Corporation | ~5.7% | Index/ETF allocations reflecting institutional stability mandates |
| FMR LLC (Fidelity) | ~4.3% | Active investor seeking operational and earnings upside |
| Geode Capital Management | ~3.5% | Systematic/global equity exposure to healthcare distribution |
- High passive ownership (Vanguard, BlackRock, State Street) supports liquidity and reduces volatility of forced selling.
- Meaningful active stakes (Wellington, Fidelity) signal expectations of improving fundamentals and strategic execution.
- Concentrated institutional ownership can influence governance, capital allocation, and strategic initiatives.
AmerisourceBergen Corporation (0HF3.L) Institutional Ownership and Major Shareholders of AmerisourceBergen Corporation (0HF3.L)
Institutional investors dominate ownership of AmerisourceBergen Corporation (0HF3.L), with institutional ownership standing at approximately 90.6%, reflecting concentrated holdings by a few large asset managers and investment firms. The following highlights the largest institutional holders and recent quarter-to-quarter changes in their stakes.- The Vanguard Group - 12,940,000 shares (9.8% of total shares); +1.2% change from prior quarter.
- BlackRock, Inc. - 10,580,000 shares (8.0% of total shares); -0.5% change from prior quarter.
- State Street Corporation - 7,210,000 shares (5.5% of total shares); +0.3% change from prior quarter.
- Wellington Management Co. LLP - 5,020,000 shares (3.8% of total shares); +0.1% change from prior quarter.
- FMR LLC (Fidelity) - 4,800,000 shares (3.7% of total shares); +0.2% change from prior quarter.
| Institution | Shares Held | % of Total Shares | Quarterly Change |
|---|---|---|---|
| The Vanguard Group | 12,940,000 | 9.8% | +1.2% |
| BlackRock, Inc. | 10,580,000 | 8.0% | -0.5% |
| State Street Corporation | 7,210,000 | 5.5% | +0.3% |
| Wellington Management Co. LLP | 5,020,000 | 3.8% | +0.1% |
| FMR LLC (Fidelity) | 4,800,000 | 3.7% | +0.2% |
| Institutional Ownership (aggregate) | N/A | 90.6% | N/A |
AmerisourceBergen Corporation (0HF3.L) Key Investors and Their Impact on AmerisourceBergen Corporation (0HF3.L)
- Vanguard Group - +1.2% change in holdings: a measurable uptick signaling increased conviction in AmerisourceBergen's strategic direction and capital allocation.
- BlackRock, Inc. - -0.5% change in holdings: a modest reduction that may reflect portfolio rebalancing or a tactical response to market conditions.
- State Street Corporation - +0.3% change in holdings: a small but positive increase consistent with a constructive view on near-term financial health.
- Wellington Management Co. LLP - new position of 300,000 shares: a clear, active bullish bet establishing material exposure.
- FMR LLC (Fidelity) - +0.2% change in holdings: continued, steady confidence in the company's growth trajectory.
- Geode Capital Management - +11% change in holdings: a significant increase implying a strong conviction in future performance or attractive valuation.
| Investor | Reported Change | Reported/Noted Position | Implication |
|---|---|---|---|
| Vanguard Group | +1.2% | Not specified (relative % change reported) | Growing strategic confidence; incremental buying pressure |
| BlackRock, Inc. | -0.5% | Not specified (relative % change reported) | Minor portfolio trimming or rotation |
| State Street Corporation | +0.3% | Not specified (relative % change reported) | Small constructive adjustment |
| Wellington Management Co. LLP | New position | 300,000 shares | Material new allocation - explicit bullish stake |
| FMR LLC (Fidelity) | +0.2% | Not specified (relative % change reported) | Steady confidence; marginal accumulation |
| Geode Capital Management | +11% | Not specified (relative % change reported) | Substantial increase indicating strong conviction |
- Market signal synthesis: concentrated increases from active managers (Wellington, Geode, Vanguard) create incremental demand and suggest conviction around operational outlook or valuation.
- Risk/positioning nuance: the minor decreases from large passive/active holders (BlackRock) temper the bullish signals, reflecting either tactical rebalancing or differing time horizons.
- Liquidity and governance impact: a new 300,000-share position and double-digit increases can shift short-term float dynamics and attract attention from other institutional investors and analysts.
AmerisourceBergen Corporation (0HF3.L) - Market Impact and Investor Sentiment
AmerisourceBergen Corporation (0HF3.L) has seen shifting investor sentiment driven by strategic M&A, rebranding, and operational investments that point to a tilt toward higher-margin specialty pharmaceuticals and stable cash flow characteristics.- Stock momentum: all-time high of $253.67 on January 27, 2025, signaling strong investor confidence in growth and execution.
- Volatility profile: low beta of 0.56, attractive to investors seeking lower correlation with market swings and greater portfolio stability.
- Analyst outlook: consensus analyst estimates for fiscal 2025 adjusted EPS have been revised upward in recent quarters, reflecting improved revenue visibility and margin expectations.
- M&A impact: the acquisition of Retina Consultants of America is forecast to add roughly $0.35 to adjusted EPS in the first year, bolstering near-term earnings accretion.
- Brand and strategy: the rebranding to Cencora in August 2023 and explicit emphasis on specialty drugs have reinforced a narrative of global reach and higher-margin product mix.
- Operational expansion: a new distribution center in California supports specialty and biologics logistics, improving service levels and supporting revenue growth in key markets.
| Metric | Value / Note |
|---|---|
| All-time high (close) | $253.67 (Jan 27, 2025) |
| Beta (30/60/90-day reference) | 0.56 |
| FY2025 adjusted EPS estimate (consensus) | Revised upward (analyst consensus increased in latest quarter) |
| Retina Consultants acquisition contribution | ~$0.35 to adjusted EPS in year 1 |
| Rebranding | Cencora (Aug 2023) - strategic global repositioning |
| Key operational expansion | New distribution center in California (specialty/biologics focus) |
| Strategic focus | Specialty drugs, provider partnerships, specialty logistics |
- Why investors are buying: stability (low beta), earnings upgrades, accretive M&A (Retina), and visible operational levers (new distribution center, specialty push).
- Sentiment drivers to monitor: execution on specialty logistics, integration of acquisitions, margin trends for specialty products, and guidance updates tied to EPS revisions.
Cencora (0HF3.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.